Welcome to the argenx

2021 R&D Day

Where critical patient need meets breakthrough science.

That is where we redefine immunology.

Advancing Towards argenx 2025
Tim Van Hauwermeiren, Chief Executive Officer and Co-Founder, argenx
Efgartigimod: Differentiation of our Anti-FcRn Fc Fragment
Hans de Haard, Chief Scientific Officer and Co-Founder, argenx
Fifth Indication: Myositis
Bas van der Woning, Research Fellow, argenx
Sixth Indication: Bullous Pemphigoid
Peter Verheesen, Research Fellow, argenx
Myositis and Bullous Pemphigoid Panel
Moderated by Albert Kovera, Global Marketing, argenx
  • Rohit Aggarwal, MD, MS – University of Pittsburgh
  • Russell P. Hall III, MD – Duke University
ARGX-117 Phase 1 Data | New Biology Insights for Multifocal Motor Neuropathy
Olivier Van de Steen, Medical Director, argenx
Inge Van de Walle, Principal Scientist, argenx
Q&A

Speakers

Bonus Content

Videos

Publications

Myositis

Bullous Pemphigoid

Efgartigimod

ARGX-117

Website Help

Should you have any questions or require assistance please contact the Q4 Inc. Investor Day support team

investordays@q4inc.com